Healthcare Industry News: S.A.
News Release - October 8, 2007
Steven Engle Appointed Chairman of XOMA
BERKELEY, Calif., Oct. 8, 2007 (Healthcare Sales & Marketing Network) -- XOMA Ltd. (NaS.A.GM:XOMA ), a leader in the discovery and development of antibody therapeutics, today announced the appointment of its Chief Executive Officer and President, Steven Engle, as Chairman of the Board of Directors effective October 5, 2007. Mr. Engle joined XOMA as its Chief Executive Officer and President and a Director in August 2007.Mr. Engle succeeds John L. (Jack) Castello, who had been Chairman, Chief Executive Officer and President of XOMA. Mr. Castello announced his plan to retire in February 2007 and agreed in August to continue serving on the Board as its non-executive Chairman through a transition period.
Mr. Engle S.A.ed, ``Under Jack Castello's leadership, XOMA has developed the financial resources, experienced team and antibody technology and capabilities required for successful product development and long-term growth. We appreciate his contributionS.A.d wish him all the best in his retirement.''
About XOMA
XOMA iS.A.leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diS.A.es. XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono S.A.) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(r) (ranibizumab injection), a monoclonal antibody product marketed worldwide (by Genentech and NovartiS.A.) to treat neovascular (wet) age-related macular degeneration.
The company has built a premier antibody discovery and development platform that includeS.A.cess to seven of the leading commercially available antibody phage display librarieS.A.d XOMA's proprietary Human Engineering(tm) and bacterial cell expression (BCE) technologies. More than 45 companies have signed BCE licenses. XOMA's development collaborators include Lexicon Pharmaceuticals, Inc., Novartis, Schering-Plough ReS.A.ch Institute and Takeda Pharmaceutical Company Limited. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch. For more information, please visit the company's website at http://www.xoma.com.
Certain S.A.ements contained herein relating to product development, long-term growth and S.A.eholder value, or that otherwise relate to future periods, are forward-looking S.A.ements within the meaning of Section 27A of the SecuritieS.A.t of 1933 and Section 21E of the Securities Exchange Act of 1934. These S.A.ementS.A.e based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the results of discovery reS.A.ch and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); uncertainties regarding the S.A.us of biotechnology patents; uncertaintieS.A. to the cost of protecting intellectual property; changes in the S.A.us of the existing collaborative and licensing relationships; the ability of collaborators, licenseeS.A.d other third parties to meet their obligations; market demand for products; S.A.e up and marketing capabilities; competition; international operations; S.A.e price volatility; XOMA's financing needS.A.d opportunities; and riskS.A.sociated with XOMA's S.A.uS.A. a Bermuda company, are described in more detail in XOMA's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.
Source: XOMA
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!